AVITA Medical & Gates Center unite to explore spray-on skin treatment
Category: #health  By Pankaj Singh  Date: 2019-11-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

AVITA Medical & Gates Center unite to explore spray-on skin treatment

AVITA Medical and Gates Center for Regenerative Medicine have reportedly inked a Sponsored Research Agreement or SRA to develop treatments for genetic skin conditions. The firms will conduct preclinical trials to develop spray-on skin treatments using genetically modified skin cells to treat epidermolysis bullosa (EB) patients as well as other genetic skin disorders.

This collaboration will bring together AVITA Medical’s patented Spray-On Skin™ Cells technology and Gates Center’s unique, patent-pending gene editing and combined reprogramming technology to improve cell function. As per the SRA terms, AVITA Medical will retain the option to obtain an exclusive license for further progression and commercialization of technologies that emerge during the collaboration.

The Gates Center team is backed by numerous prominent medical organizations. The collective efforts of the New York-based EB Research Partnership, London-based Cure EB Charity, L.A-based EB Medical Research Foundation, as well as government grants will help advance and render this technology to clinics to enhance patient lives.

Dr. Mike Perry, CEO of AVITA Medical & adjunct professor at the Gates Center has apparently stated that the Gates center has made significant strides in the treatment of genetic skin conditions, particularly epidermolysis bullosa.  He further expressed his anticipation towards working together with the Gates Center team to further advance AVITA’s Spray-On Skin™ Cells technology. The collaboration is a significant breakthrough for AVITA in their mission to harness regenerative medicine to treat unmet dermatological needs, including genetic skin disorders.

Gates Center for Regenerative Medicine Director, Dr. Dennis Roop also spoke about the partnership, expressing his eagerness to partner with AVITA Medical in an effort to further their epidermolysis bullosa program. He stated that this alliance will help discover and advance new approaches towards genetic skin conditions, by treating patients through the use of gene-edited skin cells.

Dr. Ganna Bilousova, assistant professor of dermatology & the research program’s co-principal investigator has also expressed his belief that the combination of AVITA’s Spray-On Skin™ Cells technology and Gates Center’s genetically modified skin cells will help advance their EB treatment program. Dr. Bilousova claims that this collaboration will help reduce treatment time, lower manufacturing complexity and improve treatment results, in addition to lowering costs.

Source Credit: https://www.avitamedical.com/uploads/pdf/AVH-Press-Release-EB-CU-Denver-Partnership-25NOV2019-FINAL.pdf



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication
GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication
By Pankaj Singh

 

  • The alliance is aimed at personalizing regenerative tissue manufacturing processes
  • Vascularized printed cells are set to pave the way for more complex biolog...

Hummingbird Bio secures $19M to expand antibody therapeutics portfolio
Hummingbird Bio secures $19M to expand antibody therapeutics portfolio
By Pankaj Singh

Hummingbird Bioscience, an advanced biotherapeutics company, recently announced it has raised USD 19 million in a Series B funding round. Apparently, the financing round was co-led by GNTech Venture Capital and Mirae A...

Acadia announces positive results of Phase 3 trial to treat psychosis
Acadia announces positive results of Phase 3 trial to treat psychosis
By Pankaj Singh

Acadia Pharmaceuticals, a renowned US-based biopharmaceutical company dedicated to the development of treatments for central nervous system disorders, reportedly announced positive outcomes from its Phase 3 HARMONY stu...